Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Sales (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Return on Sales for 13 consecutive years, with 0.68% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 128.0% to 0.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.33% through Dec 2025, down 96.0% year-over-year, with the annual reading at 8.33% for FY2025, 92.0% down from the prior year.
  • Return on Sales hit 0.68% in Q4 2025 for Coherus Oncology, down from 0.78% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 74.05% in Q1 2024 to a low of 2.33% in Q1 2023.
  • Historically, Return on Sales has averaged 5.18% across 5 years, with a median of 0.61% in 2021.
  • Biggest five-year swings in Return on Sales: skyrocketed 7639bps in 2024 and later crashed -7526bps in 2025.
  • Year by year, Return on Sales stood at 0.62% in 2021, then crashed by -108bps to 1.3% in 2022, then surged by 33bps to 0.87% in 2023, then surged by 32bps to 0.6% in 2024, then surged by 215bps to 0.68% in 2025.
  • Business Quant data shows Return on Sales for CHRS at 0.68% in Q4 2025, 0.78% in Q3 2025, and 33.41% in Q2 2025.